News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–49
Matches
49
Sources here
10
Companies here
1
Search results Stored financial headlines

Active search

49 matching headlines

Ticker or company: RAPPMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Moomoo Analyst action Main company 🇺🇸 United States

Goldman Sachs Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Raises Target Price to $58

Goldman Sachs has reiterated its Buy rating on Rapport Therapeutics (RAPP.US) shares. The investment bank also increased its price target for the company to $58, indicating continued confidence in the stock's performance.

RAPP main company
Sharemaestro market context Trend signal active 52 weeks +221.1% · Next-week setup positive 59.6% RAPP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

Rapport Therapeutics (RAPP) Q1 2026 earnings summary

Rapport Therapeutics reported its first-ever recognized revenue of $20.0 million in Q1 2026 from a new license agreement with Tenacia for RAP-219 in Greater China, narrowing its net loss to $19.9 million. The company announced positive Phase 2a results for RAP-219 in focal onset …

RAPP main company
Sharemaestro market context Trend signal active 52 weeks +221.1% · Next-week setup positive 59.6% RAPP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Analyst action Main company 🇺🇸 United States

TD Cowen Maintains Rapport Therapeutics(RAPP.US) With Buy Rating

TD Cowen has reiterated its Buy rating on Rapport Therapeutics (RAPP.US). The article provides a brief overview of this analyst action.

RAPP main company
Sharemaestro market context Trend signal active 52 weeks +221.1% · Next-week setup positive 59.6% RAPP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Analyst action Main company 🇺🇸 United States

RAPP Reiterates by BTIG -- Price Target Maintained at $65.00

BTIG has reiterated a 'Buy' rating for Rapport Therapeutics (RAPP), maintaining its price target at $65.00, suggesting significant upside potential from its current price of $39.92. Despite this analyst confidence, the company has a low GF Score™ of 14/100, indicating weaknesses, particularly in profitability, …

RAPP main company
Sharemaestro market context Trend signal active 52 weeks +221.1% · Next-week setup positive 59.6% RAPP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Analyst action Main company 🇺🇸 United States

Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock

Rapport Therapeutics CEO Ceesay Abraham sold shares worth $328,436 on July 14, 2026, executed under a Rule 10b5-1 trading plan. Despite the sale, Abraham retains significant direct and indirect ownership in the company, which has seen a 188% return over the past year. Analyst …

RAPP main company
Sharemaestro market context Trend signal active 52 weeks +221.1% · Next-week setup positive 59.6% RAPP stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Cổng thông tin điện tử tỉnh Lào Cai Market update Main company 🇺🇸 United States

Is Rapport Therapeutics (RAPP) stock continuing its trend (Ticks Higher) 2026-04-18 - Upside Potential

RAPP main company
Sharemaestro market context Trend signal active 52 weeks +221.1% · Next-week setup positive 59.6% RAPP stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context